ViroLogic
This article was originally published in The Gray Sheet
Executive Summary
South San Francisco, Calif.-based biotechnology firm launches PhenoSense GT HIV drug resistance test Nov. 15. The test, which integrates ViroLogic's phenotypic assay PhenoSense HIV with the firm's genotypic assay GeneSeq HIV, is the "first HIV drug resistance test to provide doctors with a single report on a patient's drug resistance profile using phenotypic test results supplemented by genotypic information," according to the firm...You may also be interested in...
ViroLogic Vying For HIV Resistance Market Advantage As Rival Mulls Merger
Surprise As FDA Approves Sarepta’s Duchenne Drug Vyondys 53
UK Set For January Brexit After Conservatives Win Election
The Conservative Party's victory in the UK general election means the Brexit withdrawal deal will be able to pass. The UK will leave the EU by 31 January and enter a transition period during which medicines regulation will remain broadly unchanged.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: